Banner News

Singapore, December 9, 2022 – Detection of Influenza virus variants


In response to the emergence of Influenza virus variants, and to mitigate any potential risks these may present to our assay performance, Credo Diagnostics conducted the BLASTn analysis (with the oligonucleotide primers and probes of the assays involving Influenza A virus detection) against the sequences of circulating Influenza A(H1N1)pdm09 variants¹ and Influenza A(H3N2) variants (seven variants belong to clade 3C.2a1b.2a.2 and one variant belongs to clade 3C.2a1b.1a) as listed in the Danish published study.²


We are pleased to announce that all our associated Influenza A assays are able to correctly detect these variant strains.


Find out more: 


For more information, contact us at



  1. The Medicines and Healthcare Products Regulatory Agency (MHRA) is aware of an emerging H1N1pdm09 influenza clade (6B.1A.5a.2 and 6B.1A.5a.1) that is circulating in the UK.
  2. Emergence of circulating influenza A H3N2 viruses with genetic drift in the matrix gene: be alert of false-negative test results. APMIS. 2022 Oct;130(10):612-617


About Credo Diagnostics Biomedical Pte. Ltd.

Credo Diagnostics develops and manufactures innovative, easy-to-use, and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas of Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.


We at Credo Diagnostics pioneer accessible diagnostic platforms to improve the lives of those we love. We believe providing the right information to the right people at the right time leads to better outcomes.